2 terminated, 1 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Completed 1 |
| Phase 1 | 1 | Terminated 1 |
Follow robatumumab: new trials by email Literature Review of robatumumab trials Research Report on robatumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Carboplatin, Epirubicin, Trastuzumab - Neoplasms | Phase 1 / Phase 2 | Terminated | Merck Sharp & Dohme LLC | 15 | 2009-09-25 | 2018-08-24 |
| A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) robatumumab - Osteosarcoma, Sarcoma, Ewing's | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 219 | 2008-02-01 | 2018-08-23 |
| A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) Robatumumab, Irinotecan, Cetuximab - Colorectal Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 67 | 2007-11-21 | 2018-08-24 |
Colorectal Neoplasms (1) · Neoplasms (1) · Neuroectodermal Tumors, Primitive, Peripheral (1) · Osteosarcoma (1) · Sarcoma, Ewing (1)
PMID 22682017, PMID 24905030, PMID 27362300
2009 (1)